Are β-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 652-657

  Alou, L ^a   Gimenez M J ^a   Sevillano, D ^a   Aguilar, L ^a   Gonzalez N ^a   Echeverria O ^a   Torrico, M ^a   Coronel, P ^b   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b Tedec Meiji Farma SA   (Spain)

Author keywords

Cefditoren; Co amoxiclav; H. influenzae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFDITOREN PIVOXIL; CEFUROXIME AXETIL; ANTIINFECTIVE AGENT; BETA LACTAM; CEFDITOREN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME SYNTHESIS; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHENOTYPIC VARIATION; STRAIN DIFFERENCE; DRUG EFFECT; HALF LIFE TIME; KINETICS; METABOLISM; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; PHENOTYPE;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; AMPICILLIN RESISTANCE; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEFUROXIME; CEPHALOSPORINS; COMPUTER SIMULATION; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HALF-LIFE; KINETICS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

EID: 34249996830     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm015     Document Type: Article

References (38)

1. Gómez J, Ruiz-Gómez J, Hernández-Cardona JL et al. Antibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: A prospective study in Murcia, Spain, 1983-1992. Chemotherapy 1994; 40: 299-303.
2. Nissinen A, Gronroos P, Huovinen P et al. Development of β-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin Infect Dis 1995; 21: 1193-6.
3. Jacobs MR, Bajaksouzian S, Zilles A et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999; 43: 1901-8.
4. Seki H, Kasahara Y, Ohta K et al. Increasing prevalence of ampicillin-resistant, non-β-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 1999; 45: 15-21.
5. Ubukata K, Shibasaki Y, Yamamoto K et al. Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Andmicrob Agents Chemother 2001; 45: 1693-9.
6. Hasegawa K, Chiba N, Kobayashi R et al. Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob Agents Chemother 2004; 48: 1509-14.
7. Garcia-de-Lomas J, Garcia-Rey C, Lopez L et al. Susceptibility patterns of bacteria causing community-acquired respiratory infections in Spain: The SAUCE project. J Antimicrob Chemother 2002; 50 Suppl S2: 21-6.
8. Doern GV, Brueggemann AB, Pierce G et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997; 41: 292-7.
9. Jones RN, Jacobs MR, Washington JA et al. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diagn Microbiol Infect Dis 1997; 27: 75-83.
10. Hasegawa K, Yamamoto K, Chiba N et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist 2003; 9: 39-46.
11. Garcia-Rodriguez JA, Baquero F, Garcia de Lomas J et al. Antimicrobial susceptibility of 1,422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-97) multicenter surveillance study. Spanish Surveillance Group for Respiratory Pathogens. Infection 1999; 27: 265-7.
12. Marco F, Garcia-de-Lomas J, Garcia-Rey C et al. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother 2001; 45: 3226-8.
13. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
14. Fenoll A, Giménez MJ, Robledo O et al. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae exhibiting nonsusceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents 2007; 29: 224-6.
15. Garcia-de-Lomas J, Lerma M, Cebrian L et al. Cefditoren activity against H. influenzae with different ampicillin susceptibility phenotypes. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract E-111. American Society for Microbiology, Washington, DC, USA.
16. Alvarez-Sala JL, Kardos P, Martinez-Beltran J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762-7.
17. Granizo JJ, Giménez MJ, Barberán J et al. Efficacy of cefditoren, focusing on S. pneumoniae and H. influenzae per-pathogen bacteriological response, in the treatment of lower respiratory tract infections: A pooled analysis of seven clinical trials. Clin Ther 2006; 28: 2061-9.
18. Dabemat H, Delmas C, Seguy M et al. Diversity of β-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother 2002; 46: 2208-18.
19. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobical - Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
20. Sevillano D, Calvo A, Giménez MJ et al. Bactericidal activity of amoxicillin against nort-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 2004; 54: 1148-51.
21. Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. Abstract 310. American Society for Microbiology, Washington, DC, USA.
22. Mulford D, Mayer M, Witt G. Effect of renal impairment on the pharmacokinetics of cefditoren. In: Abstracts of the Fortieth Intersdence Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. Abstract 311. American Society for Microbiology, Washington, DC, USA.
23. Finn A, Straughn A, Mayer M et al. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos 1987; 8: 519-26.
24. Sommers DK, Van Wyk M, Williams PE et al. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984; 25: 344-7.
25. Vree TB, Dammers E, Exler PS. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob Chemother 2003; 51: 373-8.
26. Ferslew KE, Daigneault EA, Aten EM et al. Pharmacokinetics and urinary excretion of clavulanic acid after oral administration of amoxicillin and potassium clavulanate. J Clin Pharmacol 1984; 24: 452-6.
27. Fraschini F, Scaglione F, Falchi M et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990; 2: 171-7.
28. Burkhardt O, Bomer K, von der Hoh N et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002; 50: 707-12.
29. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM et al., eds. Clinical Antimicrobial Assays, First Edition. Oxford: Oxford University Press, 1999; 35-44.
30. Martin M, Aguilar L, Balcabao IP et al. In-vitro pharmacodynamic simulation of clavulanic acid concentrations: Effect on Staphylococcus aureus and Haemophilus influenzae β-lactamase activity. J Antimicrob Chemother 1997; 39: 290-2.
31. Prieto J, Aguilar L, Gimenez MJ et al. In vitro activities of co-arnoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin. Antimicrob Agents Chemother 1998; 42: 1574-7.
32. Matic V, Bozdogan B, Jacobs MR et al. Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J Antimicrob Chemother 2003; 52: 1018-21.
33. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
34. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48: 17-28.
35. Karlowsky JA, Jones ME, Draghi DC et al. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 2002; 42 59-64.
36. Johnson DM, Biedenbach DJ, Beach ML et al. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptocoocus species. Diagn Microbiol Infect Dis 2000; 37 99-105.
37. Jones RN, Biedenbach DJ, Croco, MA et al. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalls, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31: 573-8.
38. MacGowan AP, Noel AR, Rogers CA et al. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2004; 48: 2599-603.